Edition:
India

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

16.50USD
23 Jan 2018
Change (% chg)

-- (--)
Prev Close
$16.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
25,101
52-wk High
$21.01
52-wk Low
$12.75

Latest Key Developments (Source: Significant Developments)

Mersana announces third quarter loss of $0.35 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Mersana Therapeutics Inc :Mersana announces third quarter 2017 financial results and provides business updates.Qtrly ‍loss per share $0.35​.Cash, cash equivalents and marketable securities as of Sept 30, 2017 were $133.4 million, compared with $100.3 million as of Dec 31, 2016​.Expects that cash, cash equivalents and marketable securities will enable it to fund operating plan through at least mid-2019​.  Full Article

Mersana announces FDA clearance of IND application for XMT-1536
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Mersana Therapeutics Inc :Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b.‍U.S. FDA cleared company's investigational new drug application to begin phase 1 clinical trials for XMT-1536​.  Full Article

Mersana Therapeutics says Pfizer reports 9.8 percent passive stake in Mersana as of July 3 - SEC Filing
Friday, 14 Jul 2017 

July 13 (Reuters) - Mersana Therapeutics Inc :Pfizer Inc. reports 9.8 percent passive stake in Mersana Therapeutics Inc as of July 3 - sec filing.  Full Article

Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017
Saturday, 8 Jul 2017 

July 7 (Reuters) - Rock Springs Capital Management LP: :Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing.  Full Article

Mersana Therapeutics announces pricing of initial public offering
Wednesday, 28 Jun 2017 

June 27 (Reuters) - Mersana Therapeutics Inc ::Mersana Therapeutics announces pricing of initial public offering.Says initial public offering of 5.00 million common shares priced at $15.00 per share.  Full Article

BRIEF-Mersana Announces First Patient Dosed With XMT-1536 In Phase 1 Study In Patients With NaPi2b-Expressing Tumors

* MERSANA ANNOUNCES FIRST PATIENT DOSED WITH XMT-1536 IN PHASE 1 STUDY IN PATIENTS WITH NAPI2B-EXPRESSING TUMORS Source text for Eikon: Further company coverage: